PROCESSA PHARMACEUTICALS INC (PCSA) Stock Analyst Earnings Estimates
NASDAQ:PCSA - Nasdaq - US74275C3043 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 107.2K | 113.4K 5.78% | 5K -95.59% | N/A -100.00% | N/A | N/A | 6.12M | 54.137M 784.59% | 126.39M 133.46% | 217.14M 71.80% | 328.99M 51.51% | ||||||||
| EBITDA YoY % growth | -1.729M | -748.4K 56.72% | -71.3K 90.47% | N/A -2,425.25% | N/A -113.06% | N/A 18.36% | N/A -79.87% | N/A -91.29% | N/A -80.67% | N/A 41.15% | N/A -4.73% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -2.158M | -987.2K 54.24% | -71.5K 92.76% | N/A -2,420.84% | N/A -147.79% | N/A 11.88% | -5.727M -63.56% | -11.732M -79.70% | -21.213M -75.13% | -11.387M 43.44% | -12.613M -4.74% | -11.135M 7.21% | -11.049M 0.77% | -1.842M 83.33% | 44.867M 2,536.29% | 118.3M 163.67% | 209.92M 77.45% | 321.53M 53.17% | |
| Operating Margin | -2,012.59% | -870.55% | -1,430.00% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -30.09% | 82.88% | 93.60% | 96.67% | 97.73% | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | -26.83 | -15.10 44.83% | -24.82 -68.92% | -8.67 65.32% | -4.13 55.13% | -0.55 85.84% | -0.20 62.96% | -5.51 -2,600.00% | 12.85 333.33% | 34.88 171.43% | 60.18 72.51% | 24.40 -59.46% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.12 88.12% | -0.08 88.97% | -0.06 79.60% |
| Revenue Q2Q % growth | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.777M 18.92% | -2.717M 0.66% | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.25 75.25% | -0.23 | -0.02 | -6.56% |
| Q1 2025 Q2Q % growth | -0.30 72.97% | -0.79 | 0.49 | 61.80% |
| Q4 2024 Q2Q % growth | -0.74 56.47% | -0.94 | 0.20 | 21.14% |
| Q3 2024 Q2Q % growth | -1.03 35.63% | -1.02 | -0.01 | -0.98% |
| Q2 2024 Q2Q % growth | -1.01 -330.52% | -1.00 | -0.01 | -1.04% |
| Q1 2024 Q2Q % growth | -1.11 69.17% | -1.20 | 0.09 | 7.78% |
| Q4 2023 Q2Q % growth | -1.70 76.39% | -1.63 | -0.07 | -4.17% |
| Q3 2023 Q2Q % growth | -1.60 78.38% | -2.04 | 0.44 | 21.57% |
| Q2 2023 Q2Q % growth | 96.33% | -0.23 | % | |
| Q1 2023 Q2Q % growth | -3.60 10.00% | -5.71 | 2.11 | 36.97% |
| Q4 2022 Q2Q % growth | -7.20 -71.43% | -6.53 | -0.67 | -10.29% |
| Q3 2022 Q2Q % growth | -7.40 -94.74% | -6.87 | -0.53 | -7.75% |
| Q2 2022 Q2Q % growth | -6.40 -60.00% | -4.15 | -2.25 | -54.29% |
| Q1 2022 Q2Q % growth | -4.00 -42.86% | -4.35 | 0.35 | 8.09% |
| Q4 2021 Q2Q % growth | -4.20 87.57% | -3.88 | -0.32 | -8.36% |
| Q3 2021 Q2Q % growth | -3.80 65.45% | -3.74 | -0.06 | -1.61% |
| Q2 2021 Q2Q % growth | -4.00 | -2.92 | -1.08 | -36.80% |
| Q1 2021 Q2Q % growth | -2.80 | -2.14 | -0.66 | -30.72% |
| Q4 2020 Q2Q % growth | -33.80 | -7.24 | -26.56 | -366.72% |
| Q3 2020 Q2Q % growth | -11.00 | -3.26 | -7.74 | -237.01% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 64.62% | 0% | 75% |
| Revenue | N/A | N/A | N/A | N/A |